Overview

A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer

Status:
Completed

Trial end date:
2017-04-04

Target enrollment:

Participant gender:

Summary

The aim of the study is to evaluate the objective response rate (ORR) of single agent lucitanib in metastatic breast cancer patients with FGFR1-amplified, FGFR1-non amplified with 11q amplification, or FGFR1-non amplified without 11q amplification.

Phase:

Phase 2

Details

Lead Sponsor:

Institut de Recherches Internationales Servier
Servier

Collaborator:

Breast International Group

Treatments:

Estrogens